Cargando…

In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar

BACKGROUND: Amoebiasis is a major public health problem in tropical and subtropical countries. Although a number of antiamoebic agents are used for its treatment, yet the susceptibility data on clinical isolates of Entamoeba histolytica and Entamoeba dispar are not available. Therefore, the present...

Descripción completa

Detalles Bibliográficos
Autores principales: Bansal, Devendra, Sehgal, Rakesh, Chawla, Yogesh, Mahajan, Ramesh Chander, Malla, Nancy
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC544836/
https://www.ncbi.nlm.nih.gov/pubmed/15610563
http://dx.doi.org/10.1186/1476-0711-3-27
_version_ 1782122161420369920
author Bansal, Devendra
Sehgal, Rakesh
Chawla, Yogesh
Mahajan, Ramesh Chander
Malla, Nancy
author_facet Bansal, Devendra
Sehgal, Rakesh
Chawla, Yogesh
Mahajan, Ramesh Chander
Malla, Nancy
author_sort Bansal, Devendra
collection PubMed
description BACKGROUND: Amoebiasis is a major public health problem in tropical and subtropical countries. Although a number of antiamoebic agents are used for its treatment, yet the susceptibility data on clinical isolates of Entamoeba histolytica and Entamoeba dispar are not available. Therefore, the present study was aimed to assess the in vitro susceptibility of clinical isolates of E. histolytica and E. dispar to metronidazole, chloroquine, emetine and tinidazole. METHODS: A total of 45 clinical isolates (15 E. histolytica and 30 E. dispar) were maintained in polyxenic cultures followed by monoxenic cultures. In vitro drug sensitivity (IC(50)) of clinical isolates and standard reference strain of E. histolytica (HM1: IMSS) was assessed by nitro blue tetrazolium (NBT) reduction assay after exposure to various concentrations of each drug. RESULTS: The results showed that all clinical isolates had a higher IC(50 )compared to reference strain to all the four drugs. E. histolytica isolates appeared to be more susceptible [IC(50 )(μm) 13.2,26.3,31.2 and 12.4] compared to E. dispar isolates [IC(50)(μm) 15.6,28.9,32.8 and 13.2] and the reference strain of E. histolytica [IC(50 )(μm) 9.5, 15.5, 29.9 and 10.2] to the metronidazole, chloroquine, emetine and tinidazole respectively. CONCLUSIONS: The results indicate that till date, Entamoeba isolates in India do not seem to be resistant to the commonly used antiamoebic drugs.
format Text
id pubmed-544836
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-5448362005-01-21 In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar Bansal, Devendra Sehgal, Rakesh Chawla, Yogesh Mahajan, Ramesh Chander Malla, Nancy Ann Clin Microbiol Antimicrob Research BACKGROUND: Amoebiasis is a major public health problem in tropical and subtropical countries. Although a number of antiamoebic agents are used for its treatment, yet the susceptibility data on clinical isolates of Entamoeba histolytica and Entamoeba dispar are not available. Therefore, the present study was aimed to assess the in vitro susceptibility of clinical isolates of E. histolytica and E. dispar to metronidazole, chloroquine, emetine and tinidazole. METHODS: A total of 45 clinical isolates (15 E. histolytica and 30 E. dispar) were maintained in polyxenic cultures followed by monoxenic cultures. In vitro drug sensitivity (IC(50)) of clinical isolates and standard reference strain of E. histolytica (HM1: IMSS) was assessed by nitro blue tetrazolium (NBT) reduction assay after exposure to various concentrations of each drug. RESULTS: The results showed that all clinical isolates had a higher IC(50 )compared to reference strain to all the four drugs. E. histolytica isolates appeared to be more susceptible [IC(50 )(μm) 13.2,26.3,31.2 and 12.4] compared to E. dispar isolates [IC(50)(μm) 15.6,28.9,32.8 and 13.2] and the reference strain of E. histolytica [IC(50 )(μm) 9.5, 15.5, 29.9 and 10.2] to the metronidazole, chloroquine, emetine and tinidazole respectively. CONCLUSIONS: The results indicate that till date, Entamoeba isolates in India do not seem to be resistant to the commonly used antiamoebic drugs. BioMed Central 2004-12-21 /pmc/articles/PMC544836/ /pubmed/15610563 http://dx.doi.org/10.1186/1476-0711-3-27 Text en Copyright © 2004 Bansal et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Bansal, Devendra
Sehgal, Rakesh
Chawla, Yogesh
Mahajan, Ramesh Chander
Malla, Nancy
In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar
title In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar
title_full In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar
title_fullStr In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar
title_full_unstemmed In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar
title_short In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar
title_sort in vitro activity of antiamoebic drugs against clinical isolates of entamoeba histolytica and entamoeba dispar
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC544836/
https://www.ncbi.nlm.nih.gov/pubmed/15610563
http://dx.doi.org/10.1186/1476-0711-3-27
work_keys_str_mv AT bansaldevendra invitroactivityofantiamoebicdrugsagainstclinicalisolatesofentamoebahistolyticaandentamoebadispar
AT sehgalrakesh invitroactivityofantiamoebicdrugsagainstclinicalisolatesofentamoebahistolyticaandentamoebadispar
AT chawlayogesh invitroactivityofantiamoebicdrugsagainstclinicalisolatesofentamoebahistolyticaandentamoebadispar
AT mahajanrameshchander invitroactivityofantiamoebicdrugsagainstclinicalisolatesofentamoebahistolyticaandentamoebadispar
AT mallanancy invitroactivityofantiamoebicdrugsagainstclinicalisolatesofentamoebahistolyticaandentamoebadispar